Fluoroquinolone action against mycobacteria: Effects of C-8 substituents on growth, survival, and resistance

被引:101
作者
Dong, YZ
Xu, C
Zhao, XL
Domagala, J
Drlica, K
机构
[1] Publ Hlth Res Inst City New York Inc, New York, NY 10016 USA
[2] Warner Lambert Parke Davis, Parke Davis Pharmaceut Res Div, Ann Arbor, MI 48105 USA
关键词
D O I
10.1128/AAC.42.11.2978
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Fluoroquinolones trap gyrase on DNA as bacteriostatic complexes from which lethal DNA breaks are released. Substituents at the C-8 position increase activities of N-1-cyclopropyl fluoroquinolones against several bacterial species. In the present study, a C-8-methoxyl group improved bacteriostatic action against gyrA (gyrase-resistant) strains of Mycobacterium tuberculosis and M. bovis BCG. It also enhanced lethal action against gyrase mutants of M. bovis BCG. When cultures of M. smegmatis, M. bovis BCG, and M. tuberculosis were challenged with a C-8-methoxyl fluoroquinolone, no resistant mutant was recovered under conditions in which more than 1,000 mutants were obtained with a C-8-H control. A C-S-bromo substituent also increased bacteriostatic and lethal activities against a gyrA mutant of M. bovis BCG. When lethal activity was normalized to bacteriostatic activity, the C-8-methoxyl compound was more bactericidal than its C-8-H control, while the C-8-bromo fluoroquinolone was not. The C-8-methoxyl compound was also found to be more effective than the C-8-bromo fluoroquinolone at reducing selection of resistant mutants when each was compared to a C-8-H control over a broad concentration range. These data indicate that a C-8-methoxyl substituent, which facilitates attack of first-step gyrase mutants, may help make fluoroquinolones effective antituberculosis agents.
引用
收藏
页码:2978 / 2984
页数:7
相关论文
共 30 条
  • [1] Transmission of a highly drug-resistant strain (strain W1) of Mycobacterium tuberculosis - Community outbreak and nosocomial transmission via a contaminated bronchoscope
    Agerton, T
    Valway, S
    Gore, B
    Pozsik, C
    Plikaytis, B
    Woodley, C
    Onorato, I
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 278 (13): : 1073 - 1077
  • [2] The clinical use of fluoroquinolones for the treatment of mycobacterial diseases
    Alangaden, GJ
    Lerner, SA
    [J]. CLINICAL INFECTIOUS DISEASES, 1997, 25 (05) : 1213 - 1221
  • [3] TUBERCULOSIS IN PATIENTS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION
    BARNES, PF
    BLOCH, AB
    DAVIDSON, PT
    SNIDER, DE
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (23) : 1644 - 1650
  • [4] Origin and interstate spread of a New York City multidrug-resistant Mycobacterium tuberculosis clone family
    Bifani, PJ
    Plikaytis, BB
    Kapur, V
    Stockbauer, K
    Pan, X
    Lutfey, ML
    Moghazeh, SL
    Eisner, W
    Daniel, TM
    Kaplan, MH
    Crawford, JT
    Musser, JM
    Kreiswirth, BN
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 275 (06): : 452 - 457
  • [5] BLOOM B, 1992, SCIENCE, V251, P1055
  • [6] Resistance to quinolones in mycobacteria
    Cambau, E
    Jarlier, V
    [J]. RESEARCH IN MICROBIOLOGY, 1996, 147 (1-2) : 52 - 59
  • [7] DNA gyrase and topoisomerase IV on the bacterial chromosome: Quinolone-induced DNA cleavage
    Chen, CR
    Malik, M
    Snyder, M
    Drlica, K
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 1996, 258 (04) : 627 - 637
  • [8] Fluoroquinolone action in mycobacteria: Similarity with effects in Escherichia coli and detection by cell lysate viscosity
    Drlica, K
    Xu, C
    Wang, JY
    Burger, RM
    Malik, M
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (07) : 1594 - 1599
  • [9] DNA gyrase, topoisomerase IV, and the 4-quinolones
    Drlica, K
    Zhao, XL
    [J]. MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS, 1997, 61 (03) : 377 - +
  • [10] DRLICA K, 1995, TUBERCULOSIS, P817